Background: Paeoniflorin has been proven to have neuroprotective and antidepressant effects in several studies. However, there is currently no comprehensive elaboration of its antidepressant effects through network pharmacology combined with transcriptomics analysis. The purpose of this study is to explore the potential mechanisms by which paeoniflorin exerts its antidepressant effects using network pharmacology and transcriptomics sequencing approaches. Methods: We utilized metascape to enrich the intersecting targets for paeoniflorin and depression for enrichment analyses. Additionally, we employed Cytoscape software to construct target pathway networks. For the screening of differentially expressed genes (DEGs) altered by paeoniflorin, we sequenced mRNA from the hippocampal tissue of CUMS model mice using the BMKCloud platform. We further enriched their biological functions and signaling pathways by using the Omishare database. The study utilized a combination of network pharmacology and transcriptomics analysis to evaluate the interactions between paeoniflorin and key targets. The results were then verified through a molecular docking process and a subsequent Western blot experiment. Results: According to a comprehensive analysis, paeoniflorin has 19 key targets that are closely related to its therapeutic effect. Molecular docking revealed that paeoniflorin has a high affinity for HIF-1α, VEGFA, and other targets. Furthermore, protein expression and immunofluorescence staining analysis showed that paeoniflorin significantly increased the expression level of HIF-1α and VEGFA in the hippocampus of depression model mice. Conclusion: These findings suggest that paeoniflorin may have therapeutic potential in depression through the activation of the HIF-1α-VEGFA pathway.
Depression is one of the most common neuropsychiatric disorders. The antidepressant mechanism of paeoniflorin (PF) is related to mitochondrial autophagy and inflammation has been little reported. This study aimed to investigate the anti-depressive mechanism of PF by promoting autophagy and inhibit NLRP3 activation in chronic unpredictable mild stimulation (CUMS) -induced C57BL/6 mice models in vivo and CORT-induced HT22 cell models in vitro. The reactive oxygen species (ROS) accumulation was quantified by DCFH-DA probe and detection of mitochondrial membrane potential with JC-1. Autophagy was evaluated in the hippocampus by investigating autophagosomes under transmission electron microscope (TEM) and detecting Beclin1, Parkin, P62 and LC3II/I through western blotting and immunofluorescence. NLRP3 inflammasome activation was evaluated by the expression of IL-1β, NLRP3, ASC and Caspase-1. Finally, the autophagy inhibitor 3-methyladenine (3-MA) was used to elucidate the role of autophagy in the antidepressant mechanism of PF. The results showed that PF could promote autophagic activation and cell viability of HT22 cells induced by CORT, and weaken the accumulation of ROS. Additionally, PF could alleviate CUMS induced depressive behavior and improve hippocampus damage. Moreover, it also increases the expression of autophagy related proteins in hippocampus and promote the elimination of damaged mitochondria and the generation of autophagosome. In addition, PF inhibit the expression of NLRP3 and the synthesis of NLRP3 inflammasome. The efficacy of PF was weakened by 3-MA treatment. In conclusion, PF improves CUMS-induced depressive behavior in mice and inhibits NLRP3 inflammatory mediated inflammation in vivo and in vitro, these effects may be mediated by PF induced autophagy.